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Background: Serum vitamin A, normally depressed in inflammatory conditions, is frequently low in people with CF. Vitamin A is
important in respiratory epithelial regeneration and repair. We hypothesised that serum vitamin Awould be associated with inflammation and
disease severity. Methods: Serum vitamin A (as retinol), C-reactive protein (CRP), vitamin E, 25-hydroxy vitamin D (25OHD), 1,25-
dihydroxy vitamin D (1,25(OH)2D), weight, and lumbar spine bone mineral density (LSBMD) were measured in 138 subjects with CF (5–
56 years) and 138 control subjects (5–48 years). FEV1, presence of CF liver disease (CFLD) and hospital admissions were recorded in those
with CF. Results: Serum vitamin A level was lower in CF subjects than in controls (mean, 95% CI: 1.29, 1.0–1.37 vs. 1.80, 1.7–1.87 Amol/l,
p < 0.0001), and inversely correlated with CRP (rs = 0.37, p < 0.0001). CF subjects with low vitamin A (45%) level had poorer FEV1,
weight z-score, LSBMD z-score, and higher CRP compared with those with normal levels. In the CF group CRP, vitamin E, 1,25(OH)2D,
presence of CFLD, admissions, and age were associated with vitamin A level. Conclusions: Serum vitamin A is negatively associated with
CRP in subjects with CF, consistent with normal population studies. It is important to distinguish between low serum vitamin A associated
with the inflammatory response and that due to poor nutritional stores. The role of vitamin A in CF warrants further study, in the contexts
both of chronic recurrent inflammatory disease and acute pulmonary exacerbation.
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People with cystic fibrosis (CF) are at risk for deficiency
of the fat soluble vitamins (A, D, E and K) [2]. Serum1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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E-mail address: r.greer@uq.edu.au (R.M. Greer).vitamin A levels are often suboptimal [3], and low levels
have been described in infants newly diagnosed by neonatal
screening [4,5]. Vitamin A metabolism is altered during the
acute phase response, where serum levels of vitamin A and
retinol binding protein fall transiently due to decreased
hepatic release, concurrent with increases in acute phase
proteins such as C-reactive protein (CRP) [6,7].
‘Vitamin A’, the generic term for retinoids, includes
retinol (alcohol form), retinal (aldehyde form) and retinoic
acid (acid form). Dietary carotenoids including h-carotene
are included in the vitamin A family, as they are converteded by Elsevier B.V. All rights reserved.
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providing 1 Ag retinol [8].
Biologically, vitamin A is important for vision, epithelial
differentiation and function, apoptosis, the immune system,
resistance to infectious disease, and its’ precursor h-caro-
tene has antioxidant properties. Acute inflammation causes
a reduction in serum vitamin A, ascribed to a reduction in
the hepatic synthesis of retinol binding protein, and reduc-
tion in secretion of the retinol– retinol binding protein
complex [6,9,10]. Conversely, animal studies have shown
a protective effect of both retinol (vitamin A) and h-
carotene supplementation against the inflammatory response
[11,12]. Vitamin A deficiency causes night blindness and
xerophthalmia, and is the leading cause of childhood blind-
ness in developing countries [13]. Night blindness and
xerophthalmia have been described in CF patients [14,15].
Vitamin A appears to have a role in protection of the
respiratory tract and supplementation has reduced morbidity
and mortality in infants from developing countries [16].
CF lung disease is characterised by excessive inflamma-
tory response to infection, which is present even in pre-
symptomatic infants [17,18]. Inflammation is accompanied
by neutrophilia with production of elastase and proinflam-
matory cytokines such as interleukins 6 and 8 [19]. We have
observed that serum vitamin A levels, below the normal
laboratory range in patients with severe disease, returned to
normal post lung transplant independent of oral supplemen-
tation or pancreatic sufficiency [20]. We hypothesised that
serum vitamin A is associated with inflammation and
disease severity, and that vitamin A levels would decrease
as disease severity increases with age.2. Materials and methods
2.1. Subjects
Data from the Royal Children’s Hospital paediatric and
The Prince Charles Hospital adult CF clinic subjects
(n = 138 CF (72 M) and 138 control (61 M), aged 5–56
years), in whom serum vitamin A level had been measured,
was used. Subject recruitment, and methods for vitamin D,
anthropometric indices and bone mineral density (BMD)
have been described previously [21]. Briefly, patients with
CF attending the Royal Children’s Hospital and The Prince
Charles Hospital Adult CF Clinic, Brisbane, were invited to
participate. Paediatric control subjects were recruited by
invitation from local regional schools. Adult control sub-
jects were recruited from family and friends of the inves-
tigators and subjects with CF. Most CF subjects were
studied as outpatients, except where rural or regional sub-
jects had been admitted for routine review or pulmonary
exacerbation, in which case investigations (blood samples
and bone density measurements) were undertaken after the
completion of any therapy, at least 14 days post-admission,
prior to discharge. A diagnosis of CF was confirmed with apositive sweat test. Blood samples for measurement of
serum vitamin A were protected from light.
Bone density at the lumbar spine was measured with a
Lunar DPX-L densitometer (Madison, Wisconsin).
Measurements for serum vitamin A (vitamin A), vitamin
E, 25-hydroxy vitamin D (25OHD), 1,25 di-hydroxy-vitamin
D (1,25(OH)2D), CRP, anthropometric indices, BMD and
lung function (% predicted forced expiratory volume in 1 s,
FEV1) at the time of blood collection were available. Serum
vitamin A (measured as retinol) and vitamin Eweremeasured
by an in house chromatography method used by Queensland
Health Pathology Services. Using this method, plasma is
treated with alcohol to release protein-bound retinol, which is
taken up into ethanol and chromatographed onHPLC (Waters
Alliance HPLC Integrated System). Peaks are monitored by
UV detection as 330 nm (Beckman DU 640 Spectrophotom-
eter). The coefficient of variation for measurement of serum
vitamin A is 2.6%. CRP was measured using the Beckman
IMMAGE Immunochemistry system. Serum CRP binds to
particle-bound anti-CRP antibody, forming an antigen–anti-
body complex. The IMMAGE system measures the rate of
increase in light scattered from the antigen–antibody particle
complexes. This test has a sensitivity (lowest detectable
concentration) of 0.1 mg/dl and a coefficient of variation of
6.5%. CRP was defined as elevated if >5 mg/l.
Pseudomonas aeruginosa (PSA) infection, number of
hospital admissions, pulmonary exacerbations and number
of days in hospital for the previous 12 months were
recorded. The presence of CF related liver disease (CFLD),
defined as evidence of cirrhosis on liver biopsy or portal
hypertension on ultrasound, was recorded.
Subjects with CF were routinely prescribed 1650–5000
IU vitamin A (or equivalent) daily as part of normal clinical
care. Four patients were on supplemental doses of up to
50,000 units twice weekly. Serum vitamin A levels were
defined as low if they were under the lower limit of the
normal range for our laboratory (1.0–2.3 Amol/l for subjects
under 16 years, and 1.6–2.3 Amol/l for subjects 16 years or
over).
The study was approved by the ethics committees of the
Royal Children’s Hospital and The Prince Charles Hospital.
After provision of verbal and written information about the
study, written consent was obtained from adults, parents or
carers of children, and from those children old enough to
give consent.
2.2. Statistics
Variables were described as meanF standard deviation
or age-adjusted means with 95% confidence intervals (CI)
where levels varied with age. Non-normally distributed
variables (CRP) were described as median with interquar-
tile range. Groups were compared using t-tests or analysis
of covariance to adjust for age, with control status (control
or CF) and gender considered as main effects. Tukey’s
adjustment was used for post hoc multiple comparisons.
Table 1
Characteristics of control subjects and subjects with CF by age group
Children Adolescents Adults
Control CF p Control CF p Control CF p
M/F 10/15 18/21 30/35 26/19 21/27 28/26 0.81
Age (years) 8.7F 1.5 8.5F 1.8 0.58 14.0F 2.0 14.3F 2.2 0.46 27.0F 7.5 27.3F 8.0 0.21
Weight z-score 0.35F 1.2 0.03F 1.0 0.24 0.24F 0.8  0.82F 0.9 < 0.0001 0.06F 0.5  0.34F 0.9 0.01
Height z-score 0.30F 1.1  0.24F 0.9 0.04 0.60F 1.0  0.89F 0.9 < 0.0001  0.03F 0.4  0.24F 1.0 0.16
FEV1 % 75.4F 16.9 69.0F 25.7 54.1F 20.5
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lation coefficient (rs) with adjustment (partial correlation)
for age, in order to include CRP in the correlation matrix.
Wilcoxon’s test was used to compare CRP levels. Because
physiology is different at various stages of growth, sub-
jects were divided in some instances into age groups of
children < 11 years, adolescents 11–18 years and adults
>18 years.
Predictors of serum vitamin A were examined using
multiple regression. Two multiple regression models were
examined, the first including both control and CF subjects,
and the second restricted to CF subjects to allow variables
specific to the CF group to be included in the model. In the
first multiple regression model control status, weight z-
score, vitamin E, CRP, 25OHD, 1,25(OH)2D, age, and
interaction terms for age and control status and CRP and
control status were entered as independent variables. In the
second model, restricted to CF subjects, control status was
omitted and FEV1, PSA infection, presence of CFLD,
number of admission, hospitalisation and exacerbation epi-
sodes included as independent variables, otherwise the same
predictor variables were used in both models. To further
characterise the evolution of vitamin A levels with age and
stages of growth, we also used multiple regression with
backward selection to investigate the interactions between
control status and vitamin A level in children, adolescents
and adults separately. Odds ratios were used to estimate the
risk of low serum vitamin A in those with high CRP. SAS
version 8.0 (SAS Institute, Cary, NC) was used for all
analyses.
2.3. Selection of predictive variables for vitamin A
Vitamin E, like vitamin A, is a fat-soluble anti-oxidant
and might be expected to be associated with vitamin A in
these patients with pancreatic and intestinal malabsorption.
1,25(OH)2D interacts with retinoic acid metabolism [22].Table 2
Mean, 95% confidence interval, for vitamin A (Amol/l), in male and female
CF and control subjects
Control subjects:
mean, CI
CF subjects:
mean, CI
p
Male n= 61, 1.85, 1.72–2.0 n= 72, 1.34, 1.22–1.45 < 0.0001
Female n= 77, 1.76, 1.62–1.90 n= 66, 1.24, 1.11–1.37 < 0.0001
p 0.30 0.3025OHD is the precursor for 1,25(OH)2D. Weight z-score
reflects nutritional status. FEV1, number of admissions,
hospitalisations and exacerbations are all reflectors of clin-
ical status and disease severity, while CRP is a marker for
inflammation. CFLD may affect dynamics of vitamin A
because of potentially altered secretion of retinol [10].3. Results
3.1. Vitamin A
Study subjects characteristics are described in Table 1.
Vitamin A was lower in CF subjects overall compared with
controls (1.29, 1.0 –1.37 vs. 1.80, 1.7 – 1.87 Amol/l,
p < 0.0001), increasing with age in both groups ( p < 0.0001
for relationship with age). There was no difference in vitamin
A level between genders in either the control or the CF groups
(Table 2).
When analysed by age group, vitamin A levels were
lower in adolescents and adults with CF compared with
controls, but not significantly different in children. In
children and adolescents, there was an interaction between
control status and age such that vitamin A level increased
with age in control subjects to a greater degree than in CF
subjects (Fig. 1).Fig. 1. Mean (95% CI) serum vitamin A (Amol/l) in control subjects and
subjects with CF. Serum vitamin A was not significantly different between
control and CF children (1.45, 1.25–1.64, n= 25 vs. 1.11, 0.95–1.27,
n= 39, p= 0.08) but higher in control adolescents (1.73, 1.61–1.85, n= 65
vs. 1.19, 1.05–1.34, n= 45, p< 0.0001) and adults (2.08, 1.94–2.22, n= 48
vs. 1.50, 1.37–1.63, n= 54, p< 0.0001) compared with the CF group.
Table 3
Multiple regression for predictors of vitamin A in control subjects and
subjects with CF
Predictive
independent
variables
Regression
coefficientF S.E.
p
(a) Model 1—includes control and CF subjects
Control status (control,
CF coded as 0,1)
 0.42F 0.07 < 0.0001
Vitamin E (Amol/l) 0.02F 0.004 0.0002
CRP (mg/l) control
status interaction
 0.02F 0.005 0.0006
1,25(OH)2D (pmol/l)  0.002F 0.0007 0.0005
Age (years) 0.02F 0.004 < 0.0001
(b) Model 2—restricted to CF subjects
Vitamin E (Amol/l) 0.02F 0.004 < 0.0001
CRP (mg/l)  0.02F 0.004 < 0.0001
1,25(OH)2D (pg/l)  0.003F 0.0009 0.004
CF related liver disease  0.43F 0.11 0.0001
Number of hospital admissions  0.04F 0.02 0.03
Age (years) 0.02F 0.004 < 0.0001
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The prevalence of low serum vitamin Awas higher in the
CF group compared with controls ( p < 0.0001). Forty-five
percent (62/138, 32M) of CF subjects had low vitamin A and
55.1% (76/138, 34 M) had normal levels, compared with
11.6% (16/138, 12 M) of control subjects with low levels and
88.4% (122/138, 65 M) with normal levels. In the CF group,
30.8% (12/39) children, 44.5% (20/45) adolescents and
55.6% (30/54) adults had a low level of vitamin A. In the
control group, 16.0% (4/25) children, 3.1% (2/65) adoles-
cents and 20.8% (10/48) adults had low levels. The propor-
tion of subjects with low vitamin Awas different according to
age group in the control subjects ( p= 0.01), but similar in the
CF group ( p = 0.06). In children, prevalence of low vitamin
A was similar in the control and CF groups ( p = 0.18) but
prevalence was increased in adolescents ( p < 0.0001) and
adults ( p = 0.0003) with CF compared with controls.
Ten subjects had CFLD, 3 children (2 M), 3 adolescents
(3 M), and 4 adults (2 M). Serum vitamin A level was lower
in the group with CFLD (0.82, 0.48–1.17, vs. 1.57, 1.50–
1.64 Amol/l, p = 0.003). A greater proportion of subjects
with CFLD had low vitamin A level (10/14 (71.4%)
compared with 52/124 (42%) without CFLD, p = 0.04).
There was no difference in vitamin A level between
pancreatic insufficient (n = 130, 70 M) and sufficient sub-
jects with CF (n = 8, 2 M) (1.28F 0.5 vs. 1.36F 0.8 Amol/l,
p = 0.80). There was no difference in vitamin A level
between the 4 subjects with CF who were on high dose
vitamin A supplementation compared with those on routine
supplementation, nor any difference between the 11 patients
(9 children, 2 adults) free of PSA and the other patients.
In CF subjects, FEV1 (70.6F 21.8 vs. 57.9F 23.1 %,
p = 0.001), weight z-score ( 0.12F 0.98 vs.  0.76F 0.94,
p = 0.0002), and lumbar spine BMD z-score ( 0.50F 1.24
vs. 1.08F 1.31, p = 0.009) were lower in patients with low
vitamin A. There was no difference in height z-score
between those with low vitamin A and those with vitamin
A in the normal range ( 0.35F 0.91 vs.  0.55F 1.13,
p = 0.27). CRP was higher (median = 7.0, IQR= 2.0–14.0
vs. median = 1.0 IQR = 1.0–3.0 mg/l, p < 0.0001) in CF
subjects with low vitamin A. There were no gender differ-
ences in FEV1, weight z-score or CRP in those with low
vitamin A vs. those with levels in the normal range. Lumbar
spine BMD z-score was lower in male subjects with low
vitamin A (n = 30) vs. those with normal levels (n = 42)
( 1.53F 1.44 vs.  0.58F 1.42, p = 0.009), but no differ-
ent in females with low (n = 32) vs. normal (n = 34) vitamin
A levels ( 0.66F 1.03 vs.  0.43F 0.99, p = 0.88). Thus
the difference in bone mineral density was attributable
mainly to the male group. Lumbar spine BMD z-score was
similar in males and females with normal vitamin A levels
( p = 0.96), but lower in males than in females in those with
low levels ( p = 0.03).
CRP was available in 133 subjects with CF, high in 51,
and in 136 control subjects, high in 17. CRP was correlated
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controls (rs = 0.06, p= 0.45). CRP was higher in CF subjects
compared with control subjects (median 3.0, IQR 1.0–10.0,
n = 133, vs. median 2.0, IQR 1.0–3.0 mg/l, n = 136,
p = 0.04). CRP was negatively correlated with vitamin A
in CF subjects (rs = 0.37, p < 0.0001), but not in control
subjects (rs = 0.01, p = 0.9), and correlated in CF subjects
with FEV1 (rs = 0.42, p < 0.0001).
3.3. Predictors of vitamin A level
In the first multiple regression model, control status,
vitamin E, 1,25(OH)2D, age, and the interaction between
CRP and control status were predictive of vitamin A level, the
interaction term indicating that CRP was predictive in CF but
not in control subjects (Table 3a). Weight z-score and 25OHD
vitamin D were not significant predictors. These predictors
explained 36% of the variation in vitamin A (r2 = 0.36).
In the second multiple regression model restricted to the
CF group, CRP, vitamin E, and 1,25(OH)2D, presence of
CFLD, number of admissions, and age, but not FEV1,
weight z-score, number of hospitalisations or exacerbations,
were predictive (Table 3b). Significant predictors explained
49% of the variation in vitamin A (r2 = 0.49).
High CRP was a risk factor for low serum vitamin A in
the CF group (OR 6.39, CI 2.93–13.90), where 37 of those
with high CRP had low vitamin A. None of the control
subjects with high CRP had low vitamin A.4. Discussion
This study demonstrates that serum vitamin A levels are
inversely proportional to CRP in subjects with CF. This is
consistent with reports from large epidemiological studies
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decreased serum retinol associated with inflammation is not
caused by nutritional vitamin A deficiency. Indeed, in
studies aimed at measuring prevalence of nutritional vitamin
A deficiency, presence of inflammation is a confounder. In
non-CF populations, serum vitamin A decreases transiently,
proportionate to the rise in CRP, as part of the normal acute
phase response to inflammation [6,24]. The inverse relation-
ship between serum retinol and inflammation is notably well
documented in Stephensen and Gildengorin’s analysis of
data from more than 22,000 subjects in large third National
Health and Nutrition Examination Survey (NHANES III)
[23], as well as in smaller studies of specific inflammatory
episodes [24]. The mechanism for these changes is not at
present entirely understood, but several factors have been
elucidated. Hepatic vitamin A release is decreased concur-
rent with impaired synthesis or release of retinol binding
protein and transthyretin from the liver [6,7,10,24]. Oxida-
tive stress and free radical production associated with
inflammation may increase metabolic requirement for vita-
min A [25], and urinary retinol loss during severe infections
has been associated with decreased serum retinol [26].
Cystic fibrosis is a case of inflammatory disease where
the insult is repeated, and associated with progressive tissue
damage, complicated by liver disease in around 10–15% of
patients. A re-evaluation of the role of vitamin A in CF is
required. Nutritional deficiency must be differentiated from
low serum retinol associated with the inflammatory re-
sponse. Nutritional vitamin A deficiency in CF subjects
has been clearly documented in the literature. Low serum
retinol levels, which recovered with supplementation and
enzyme replacement, have been reported in infants with CF
diagnosed by neonatal screening [4,27]. Night blindness and
xerophthalmia have been reported [14,15], although these
complications appear rare. Their association with serum
vitamin A level is likely to be multifactorial, and prospective
studies are needed. In recent years, enhanced understanding
of nutritional issues in CF, and the widespread recommen-
dation of routine daily vitamin A supplementation [2]
perhaps make the occurrence of true vitamin A deficiency
in CF less likely. However issues of imperfect medication
adherence [28], and the prolonged nature of the inflamma-
tory process in CF, suggest that some subjects may be at risk
of suboptimal stores. Lindblad et al. [29] documented
decreasing concentration of vitamin A in the liver with
age. It is likely that in clinical practice there is an overlap
in these two scenarios, with some patients having nutritional
deficiency and low liver stores, as well as low serum levels
associated with inflammation, while other patients have
adequate liver stores with low serum levels associated with
inflammation alone, but not nutritional deficiency.
This is exemplified in the current study, where 61% of
CF patients with serum vitamin A level below the normal
range also had elevated CRP, however the remaining 39% of
CF subjects with low vitamin A had normal CRP. Despite
the possibility that adoption of an arbitrary cutoff point inchildren and adults may engender some misclassification,
this observation suggests that a number of subjects had low
serum vitamin A not associated with the acute inflammatory
response.
The overlap between nutritional and inflammatory
changes in serum vitamin A level is important, because
nutritional vitamin A deficiency (possibly compounded by
increased requirement) is theoretically treatable by increased
supplementation or improved attention to adherence. Also,
pulmonary exacerbation in patients with prolonged inflam-
matory disease, and pre-existing low or marginal tissue
stores of vitamin A, might precipitate deficiency with
serious consequences, including impairment of the immune
response and of epithelial regeneration [30].
Our finding of a significant proportion of CF subjects with
low serum vitamin A is in agreement with previous studies
[3,4,27,31–33]. The normal increase in serum vitamin A
with age was attenuated in CF subjects, who had significant-
ly lower levels in adolescence and adulthood than controls.
Vitamin A level was negatively associated with CRP, which
increased with age in the CF group. This association of
vitamin A and CRP is consistent with the work of Duggan et
al. [34], who found that CRP was negatively correlated with
vitamin A level in adult CF patients admitted for pulmonary
exacerbation. Examination of the relationship between age
and vitamin A separately in children, adolescents and adults
provided an additional insight. There was an increasing
disparity in mean vitamin A level between CF and control
groups with age, suggesting an association with disease
progression independent of pancreatic or intestinal malab-
sorption, in agreement with the findings of Lancelotti et al.
[32], who found that serum vitamin A levels were not
associated with pancreatic sufficiency status.
The clinical significance of reduced serum vitamin A
levels in CF is not known. We found that CF subjects with
low serum vitamin A had lower levels of lung function,
lower weight z-score and lower bone mineral density than
those with normal vitamin A level, but any causal relation-
ship, including interaction with inflammatory status,
requires further investigation.
The association with 1,25(OH)2D is a new observa-
tion. The highly significant negative relationship with
1,25(OH)2D, which did not differ in the regression with
all subjects or that confined to CF subjects, may be
related to immune modulatory and gene regulatory effects
of both vitamin A and 1,25OH2D, which interact at the
level of the retinoic acid receptor (RXR) and vitamin D
receptor (VDR) [22].
Cawood et al. [35] using tracer techniques found that
whilst post-prandial retinol was comparable in CF and
control subjects, serum levels followed up from 7 to 28
days gradually declined in controls but were undetectable at
any stage in the CF group. These results are indicative of
reduced vitamin A mobilisation from the liver in spite of
reduced serum levels. These data are supported by the
known upregulation of hepatic stellate cells, responsible
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in some patients with CF [36]. Our findings are also in
agreement with the conclusions of Rosales et al. [10], who
showed in rats that inflammation-induced hyporetinaemia
was the result of reduced hepatic synthesis of retinol binding
protein, and reduced secretion of the retinol binding pro-
tein–retinol complex from the liver. Rosales and Ross [37]
further showed, in both vitamin A supplemented and non-
supplemented rats, that inflammation-induced hyporetinae-
mia represents tissue re-distribution of vitamin A rather than
a loss of vitamin A. The presence of a hepatic transport
defect, or defect of hepatic retinol release, is also supported
by the work of Lepage et al. [38], who found improvement
in the serum retinol/RBP ratio following ursodeoxycholic
acid (URSO) treatment in children with CF. However
Lindblad et al. [29] found that liver vitamin A level
decreased with age in supplemented CF subjects aged 8–
34 years, suggesting that low serum levels were not entirely
attributable to a hepatic transport defect, and providing
evidence for the safety of routine supplementation.
Serum retinol binding protein, which may aid interpre-
tation of serum vitamin A in the light of inflammatory status
and liver function, was not measured and is a limitation of
this study [24]. In addition, adherence with pancreatic
enzyme replacement and/or vitamin supplementation was
not assessed. Nevertheless serum vitamin A measurement is
readily available, and currently the recommended tool to
evaluate vitamin A status [39], but must be interpreted in the
light of concurrent inflammatory status.
The clinical questions raised by this study are whether
low serum vitamin A levels in CF are due to nutritional
vitamin A deficiency, the inflammatory response, or a
combination of both. Wood et al. [40] found improvement
in lung function in CF subjects receiving high-dose anti-
oxidant supplementation. The role of the liver in vitamin A
storage and transport in CF needs clarification. Studies are
needed to determine the importance of serum vitamin A in
the pathophysiology of lung disease in CF, and the potential
role of supplementation (with appropriate surveillance for
potential adverse effects), in the contexts of both chronic
inflammatory disease and acute pulmonary exacerbation.Acknowledgements
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